With the rapid follow-up of domestic generic drugs for chronic respiratory diseases in recent years, and the innovative preparations for inhaling vaccines, antibodies and other drugs to reach the lungs and enter the circulatory metabolism under the catalysis of epidemic situation, enterprises in the pharmaceutical field at home and abroad are gradually paying attention. According to the data disclosed by WHO, there are 600 million patients with chronic respiratory diseases in the world, and there are 150 million patients with chronic respiratory diseases in China, including asthma and COPD. For patients with chronic respiratory diseases, the commonly used methods of administration are inhalation, oral administration, intravenous administration, transdermal administration, etc. Among them, inhalation administration can be skillfully combined with physiological and histological characteristics such as respiratory system, directly acting on respiratory tract and lungs, taking effect quickly, avoiding the first-pass effect of liver, and having low dosage and toxicity. Inhalation drug delivery devices are mainly divided into aerosol (MDI), dry powder (DPI), atomized inhalation (NEM), etc., as well as new drug delivery devices that overseas pharmaceutical companies pay more attention to in recent years, such as intelligent drug delivery devices and precise atomizing (or Soft-mist Inhaler) devices.